You are here
NANOVIR, LLC.
UEI: N/A
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Pre-clinical Development of a Broad Spectrum Antiviral Compound to Treat Human Pa
Amount: $3,000,000.00DESCRIPTION (provided by applicant): The proposal seeks support for the pre-clinical development of broad spectrum compounds for treatment of human papillomavirus (HPV). HPV, the most common sexually- ...
STTRPhase II2010Department of Health and Human Services National Institutes of Health -
Pre-Clinical HPV16 Antiviral Compound Development
Amount: $2,942,780.00DESCRIPTION (provided by applicant): Human Papillomavirus (HPV) 16 is by far the major cause of cervical dysplasia and cancer, but no effective treatment for the virus is available or anticipated. Maj ...
SBIRPhase II2008Department of Health and Human Services National Institutes of Health -
Pre-Clinical HPV16 Antiviral Compound Development
Amount: $2,942,780.00STTRPhase II2008Department of Health and Human Services National Institutes of Health -
Antiviral Compounds that Target HPV18 DNA
Amount: $480,768.00DESCRIPTION (provided by applicant): This project will identify imidazole-pyrrole polyamides to be used as topical antiviral agents for the treatment of human papillomavirus (HPV). Current treatments, ...
STTRPhase I2007Department of Health and Human Services National Institutes of Health -
Antiviral Compounds for Human Papillomavirus 16
Amount: $599,383.00This project seeks imidazole-pyrrole polyamides to be used as topical antiviral agents for the treatment of human papillomavirus (HPV). HPV, especially in its sexually-transmitted forms, presents a ma ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health
